2018
DOI: 10.3892/etm.2018.6020
|View full text |Cite
|
Sign up to set email alerts
|

MicroRNA‑216b‑3p inhibits lung adenocarcinoma cell growth via regulating PDZ binding kinase/T‑LAK‑cell‑originated protein kinase

Abstract: Numerous studies have reported that microRNA (miR)-216b, as a tumor suppressor, is downregulated in a variety of cancer types. PDZ binding kinase (PBK)/T-LAK-cell-originated protein kinase (TOPK) is highly expressed in various types of human cancer, including lung cancer. The expression of miR-216b-3p and its potential roles in lung adenocarcinoma are still unclear and no research has been conducted into the association between miR-216b-3p and PBK/TOPK. Thus, the present study aimed to investigate the expressi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
6
0

Year Published

2018
2018
2021
2021

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 10 publications
(7 citation statements)
references
References 42 publications
(41 reference statements)
0
6
0
Order By: Relevance
“…miRNAs can interact directly with the 3’-untranslated region of target mRNAs and lead to inhibition of proliferation, differentiation, metastasis, and apoptosis [ 125 ]. For instance, miR-216b and miR-770-5p have been demonstrated to inhibit proliferation of lung adenocarcinoma and breast cancer by targeting TOPK [ 57 , 112 ]. In addition, evidence demonstrates that patients with KRAS, BRAF, or PTEN mutations experience fewer clinical responses to drugs such as cetuximab and panitumumab.…”
Section: Discussion and Perspectivesmentioning
confidence: 99%
See 1 more Smart Citation
“…miRNAs can interact directly with the 3’-untranslated region of target mRNAs and lead to inhibition of proliferation, differentiation, metastasis, and apoptosis [ 125 ]. For instance, miR-216b and miR-770-5p have been demonstrated to inhibit proliferation of lung adenocarcinoma and breast cancer by targeting TOPK [ 57 , 112 ]. In addition, evidence demonstrates that patients with KRAS, BRAF, or PTEN mutations experience fewer clinical responses to drugs such as cetuximab and panitumumab.…”
Section: Discussion and Perspectivesmentioning
confidence: 99%
“…Furthermore, the expression of p53, its target gene, and cyclin-dependent kinase inhibitor p21 are upregulated in TOPK knockdown experiments [ 18 ]. Activation of TOPK in cancer may be promoted by inhibiting microRNA-mediated regulation [ 57 ]. In addition, restoration of miR-216b-3p expression in cancer cells is sufficient to inhibit proliferation, promote apoptotic cell death, and overcome TOPK-related downregulation of p53 and p21 [ 58 ].…”
Section: Topk Induces Apoptosis Resistance In Tumor Cellsmentioning
confidence: 99%
“…TOPK overexpression in cancer appears to be facilitated by suppression of microRNA-mediated regulatory control. Restoration of miR-216b-3p expression in lung cancer cell lines is sufficient to inhibit proliferation, enhance apoptotic cell death and overcome TOPK-associated down-regulation of p53 and p21 20 .…”
Section: Preclinical Rationale: Topk Overexpression In Cancermentioning
confidence: 99%
“…It was also reported as hub gene in diffuse large B-cell lymphoma (42). Besides, PBK also played important roles in other cancers, including lung adenocarcinoma (43, 44). Moreover, KNSTRN [Kinetochore Localized Astrin (SPAG5) Binding Protein], which was essential for the mitotic spindle, faithful chromosome segregation and progression into anaphase, was reported to be involved in pathogenesis of leukemias (45), basal cell carcinoma (46).…”
Section: Discussionmentioning
confidence: 99%